Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Inflammatory biomarkers in Alzheimer's disease plasma

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Declining incidence of dementia: A national registry-based study over 20 years

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Blood Metabolite Signatures of Metabolic Syndrome in Two Cross-Cultural Older Adult Cohorts

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Lipidomic profiles, lipid trajectories and clinical biomarkers in female elite endurance athletes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Describing the fecal metabolome in cryogenically collected samples from healthy participants

    Research output: Contribution to journalJournal articleResearchpeer-review

  • NIMA Consortium
View graph of relations

INTRODUCTION: Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers.

METHODS: A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed.

RESULTS: Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71).

DISCUSSION: Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.

Original languageEnglish
JournalAlzheimer's & dementia : the journal of the Alzheimer's Association
Volume15
Issue number6
Pages (from-to)776-787
Number of pages12
ISSN1552-5260
DOIs
Publication statusPublished - 1 Jun 2019
Externally publishedYes

Bibliographical note

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

    Research areas

  • Alzheimer's disease, Biomarker, Complement, Inflammation, Plasma

ID: 57306877